Her Heart Attack Was Missed Because No One Wanted to Move Her Bra

The Dangerous Intersection of Modesty, Electrode Misplacement, and the Sex Disparity That Is Killing Women With STEMI

She is 58 years old. She has been nauseated for an hour, with pressure in her jaw and a dull ache between her shoulder blades. She calls 911. Paramedics arrive and begin a 12-lead ECG. But something goes wrong before the first tracing is even printed.

The paramedic hesitates. She is a woman, and her breast tissue covers the landmarks where leads V3 through V6 should be placed. Rather than positioning the electrodes beneath the breast — where they belong anatomically — the electrodes are placed on top of it, or slightly above the correct intercostal space. V1 and V2 are displaced upward because the provider is rushing, avoiding the need to palpate too close to the breast. The ECG prints. The tracing looks unremarkable.

She is transported to a community hospital. Not a PCI center. Not a cath lab. Because the ECG didn’t show what it should have shown.

Her anterior STEMI was there. The electrodes just weren’t in the right place to see it.

This is not a hypothetical. This pattern — modesty-driven electrode misplacement leading to delayed or missed STEMI diagnosis in women — is documented in the medical literature, acknowledged by professional guidelines, and reflected in outcome data that shows women consistently receive slower, less aggressive cardiac care than men. It is a disparity that is costing lives. And it is a disparity that is entirely unnecessary.

The Data That Defines a Crisis in Women’s Cardiac Care

Cardiovascular disease is the leading cause of death for women in the United States, killing approximately 310,000 women annually — roughly 1 in every 5 female deaths (CDC, 2024; AHA 2024 Heart Disease and Stroke Statistics). Yet at every stage of the STEMI care continuum, women receive care that is measurably slower and less definitive than men.

9.4%

In-hospital STEMI mortality rate for women vs. 4.5% for men — more than double. (AHA Newsroom, study of 45,000+ patients, 2002–2016)

14%

of women with STEMI received a prehospital ECG within 10 minutes vs. 29% of men. Women waited significantly longer for their first diagnostic ECG. (Muhrbeck et al., International Journal of Cardiology Heart & Vasculature, 2020)

12.2%

longer door-to-balloon times in women vs. men, even after accounting for age, race, and mode of arrival. (Prehospital Emergency Care, 2024 — study of 3,153 STEMI activations)

72.8%

of women saw a cardiovascular specialist during their MI hospitalization vs. 84% of men. Women were also less frequently prescribed beta blockers and cholesterol-lowering drugs at discharge. (AHA Newsroom)

A 15-year nationwide analysis published in the Journal of the American Heart Association found that sex-based disparities in diagnostic evaluation and revascularization for STEMI improved over time, but still existed in the most recent study period (2017–2019). Risk-adjusted in-hospital mortality remained higher for women after PCI for STEMI. Female sex was an independent predictor of in-hospital mortality (p=0.04). The authors concluded that the disparity was “likely secondary to the delayed presentation of women to the hospital for primary percutaneous coronary intervention.”

A 2025 study in the European Heart Journal analyzing 10,229 STEMI patients from the Irish Heart Attack Audit (2017–2023) confirmed that women had significantly higher odds of in-hospital mortality even after adjusting for age and key clinical factors.

The pattern is consistent across countries, registries, and decades: women with STEMI wait longer for diagnosis, receive less aggressive treatment, and die at higher rates. The question is: why?

The Electrode Placement Problem No One Talks About

There are multiple reasons for the disparity in women’s STEMI outcomes, including atypical symptom presentation, lower awareness of cardiac risk in women, and systemic biases in triage. But there is one contributing factor that is uniquely preventable and alarmingly under-addressed: the misplacement of ECG electrodes on female patients due to breast tissue and modesty concerns.

A systematic review by Hadjiantoni et al. (2021) published in Cardiology and Cardiovascular Medicine found that challenges with lead placement arise in patients with large breast tissue because ECG professionals may not be able to locate bony landmarks in the chest. The same review noted that paramedics could make errors in lead placement due to fears or embarrassment about exposing female patients’ breast tissue.

This is not a minor technical footnote. It is a patient safety crisis hiding behind clinical etiquette.

Here is what happens clinically when modesty overrides accuracy:

V1 and V2 are placed too high. When a provider avoids palpating near the breast to identify the 4th intercostal space, V1 and V2 frequently end up in the 2nd or 3rd intercostal space. Walsh (2018) demonstrated in the American Journal of Emergency Medicine that this misplacement can generate false ST-segment elevation (triggering unnecessary cath lab activations) or mask genuine anterior wall ischemia.

V3, V4, V5, and V6 are placed on top of the breast. The Society for Cardiological Science and Technology (SCST) guidelines state that when breast tissue covers placement areas, electrodes V4, V5, and V6 should be placed under the breast. However, research in the Emergency Medicine Journal found that more than half of female patients prefer leads on their breast rather than under it. When providers follow this preference or avoid the conversation entirely, electrodes end up on top of breast tissue, which acts as an electrical insulator. Clinical evidence indicates this can reduce signal amplitude by 30–40%, flattening T-waves, reducing R-wave amplitude, and mimicking ischemic patterns — or hiding real ones.

The result: lateral and anterior wall changes that define a STEMI can be attenuated to the point of invisibility. A heart attack that is actively occurring may produce a tracing that looks normal or non-specific — because the electrodes that were supposed to detect it were sitting on top of breast tissue instead of underneath it, in proper anatomical contact with the chest wall.

⚠ One textbook, cited in Gender in the Genome, advises removing a patient’s necktie in cases of acute MI but does not mention bras. This reflects the broader training gap: medical education often teaches ECG placement on flat male chests, leaving providers unprepared for the anatomical and interpersonal challenges of acquiring a diagnostic-quality ECG on a female patient.

A GE HealthCare analysis noted that while electrode misplacement affects more than 50% of all patients across both sexes (frequently in V1 and V2, per Circulation), anatomical differences specifically complicate correct placement in women. The compound effect is that women are disproportionately vulnerable to both false-positive and false-negative ECG findings from the very first tracing.

Every Minute Matters — and Women Are Losing More of Them

The ACC/AHA guidelines are unequivocal: an ECG should be acquired and interpreted within 10 minutes of first medical contact for patients with suspected ACS (2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes). For STEMI, primary PCI should occur within 90 minutes of first medical contact at a PCI-capable center.

Women are failing to meet these benchmarks at significantly higher rates than men.

In a Swedish study of 539 STEMI patients, only 14% of women received a prehospital ECG within 10 minutes of ambulance arrival, compared to 29% of men (p=0.001). Women had longer delays from symptom onset to first medical contact (median 90 vs. 66 minutes, p=0.04) and longer delays to diagnostic ECG (median 146 vs. 103 minutes, p=0.03) (Lawesson et al., BMJ Open, 2018).

A large Chinese registry of over 1.1 million STEMI patients (2016–2023) found that women consistently experienced longer prehospital delays than men (median 170 vs. 124 minutes), driven primarily by longer EMS call delays — with the sex gap widening, not narrowing, at the most extreme delay times.

These delays are deadly. De Luca et al., publishing in Circulation (AHA), demonstrated that the relative risk of one-year mortality increases by 7.5% for every 30 minutes of treatment delay in STEMI patients undergoing primary PCI (adjusted RR 1.075; Circulation, 2004). For patients in cardiogenic shock, the FITT-STEMI trial found that every 10 minutes of delay resulted in 3.31 additional deaths per 100 PCI-treated patients (Scholz et al., European Heart Journal, 2018).

When a woman’s ECG takes longer to acquire, shows attenuated signals from breast tissue, or is misread because electrodes were placed in the wrong intercostal space, every link in the STEMI chain of survival is weakened. The cath lab may not be activated. The PCI-capable center may not be selected. The reperfusion therapy may be delayed. And the myocardium dies.

Atypical Symptoms + Electrode Misplacement = A Perfect Storm

Women are already disadvantaged by the fact that they are more likely than men to present with atypical MI symptoms — nausea, jaw pain, back pain, fatigue, and shortness of breath rather than classic crushing chest pain. The AHA has consistently emphasized that atypical presentations occur in approximately 30% of STEMI cases, and are particularly common in women, elderly patients, and those with diabetes.

This means the ECG may be the only objective tool that can identify the cardiac event in real time. If that ECG is compromised by electrode misplacement — V1/V2 too high, V4–V6 on top of the breast, limb leads placed on the torso — the one diagnostic lifeline these patients have is severed.

Consider the cascade:

1. 1. A woman presents with “atypical” symptoms. The clinical index of suspicion for MI is already lower.
2. 2. An ECG is performed, but the provider hesitates over electrode placement near the breast. V1/V2 go too high. V4–V6 are placed on top of breast tissue.
3. 3. The tracing is attenuated or artifact-ridden. ST-segment changes that would confirm STEMI are obscured.
4. 4. The provider interprets the ECG as non-diagnostic. The cath lab is not activated. The patient is transported to a lower-acuity facility or observed instead of treated.
5. 5. By the time the true diagnosis is made, irreversible myocardial damage has occurred.

This sequence doesn’t require malice. It doesn’t require incompetence. It only requires a moment of hesitation about where to put the stickers — and a healthcare system that has never adequately trained its providers to navigate that hesitation.

Our Duty: Accurate ECG Acquisition Is Not Optional

The disparity in women’s STEMI care is not inevitable. It is not an acceptable byproduct of anatomical difference. It is a failure of technology, training, and systems design that we have the ability — and the obligation — to fix.

Every clinician who acquires an ECG has a professional duty to place electrodes in the correct anatomical position regardless of the patient’s sex, body habitus, or breast tissue. The SCST, AHA, and ACC guidelines are clear: diagnostic accuracy must take precedence over convenience or discomfort. A brief, professional explanation to the patient about the importance of proper electrode placement is all that is needed to navigate the modesty concern while preserving life-saving diagnostic fidelity.

But we also need to acknowledge the truth: the current ECG acquisition system — 10 individual electrodes applied one at a time, requiring manual identification of intercostal spaces, with no built-in guidance for breast tissue management — was designed for male anatomy. It has remained essentially unchanged for over 70 years. And it is failing women.

C-Booth Innovations developed the EXG™ Wearable ECG Platform to address this exact failure. By consolidating precordial electrode placement into a single, anatomically guided, wearable system, the EXG eliminates the guesswork that leads to misplacement. A provider aligns the central device over the sternum with a nipple-line marker, and all six chest electrodes are positioned simultaneously in their correct anatomical locations — reducing the need to individually navigate around breast tissue while still maintaining proper positioning beneath it.

The result is a system that removes the primary barrier to accurate ECG acquisition in women: the hesitation. There is no need to individually palpate each intercostal space near the breast. There is no ambiguity about whether electrodes should go on top of or underneath breast tissue. The device is designed to provide correct placement by default.

The EXG is FDA registered, ISO certified, designed to AHA-compliant standards, radiolucent, and expandable from 12-lead to 18-lead for enhanced STEMI detection. It deploys in under 60 seconds and maintains continuous diagnostic-quality monitoring from the field through the cath lab.

The Uncomfortable Truth We Must Confront

Women with STEMI are dying at higher rates than men. They are waiting longer for their first ECG. They are receiving slower reperfusion therapy. They are being seen less frequently by cardiovascular specialists. And part of the reason — a preventable, addressable, unacceptable part of the reason — is that we are not placing ECG electrodes correctly on their bodies.

Every compromised ECG on a female patient represents a potential missed diagnosis. Every missed diagnosis represents potential irreversible myocardial damage, heart failure, or death. And every one of those outcomes was avoidable if we had the right technology, the right training, and the right commitment to diagnostic accuracy regardless of sex.

The data from the AHA, ACC, and peer-reviewed journals is unambiguous: the sex disparity in STEMI care exists, it is deadly, and electrode misplacement driven by breast tissue and modesty concerns is a documented contributor. We have an obligation — clinical, ethical, and moral — to perform every 12-lead ECG accurately. No patient should receive a compromised cardiac diagnosis because a clinician was uncertain about where to place a sticker.

The technology to solve this problem exists. The question is whether we have the will to adopt it.

References

1. American Heart Association. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data. Circulation. 2024.
2. American Heart Association Newsroom. Women found to be at higher risk for heart failure and heart attack death than men. (Study of 45,000+ patients, 2002–2016, Alberta, Canada.)
3. Beirne E, et al. Sex based disparities in STEMI outcomes: higher in-hospital mortality in women from a national registry of 10,229 patients. European Heart Journal. 2025;46(Suppl 1):ehaf784.1666.
4. Hadjiantoni A, Oak K, Mengi S, et al. Is the correct anatomical placement of the ECG electrodes essential to diagnosis in the clinical setting: a systematic review. Cardiology and Cardiovascular Medicine. 2021;5(2):182–200.
5. GE HealthCare. Best Practices for ECG Lead Placement on Women. 2021.
6. Walsh B. Misplacing V1 and V2 can have clinical consequences. American Journal of Emergency Medicine. 2018;36(5):865–870.
7. Campbell B, Richley D, Ross C, Eggett CJ. Clinical guidelines by consensus: recording a standard 12-lead ECG. Society for Cardiological Science and Technology (SCST). 2017.
8. Wallen R, Tunnage B, Wells S. Female patients’ preference for electrode placement during resting ECG. Emergency Medicine Journal. (Cited via GE HealthCare.)
9. Muhrbeck J, Maliniak E, Eurenius L, Hofman-Bang C, Persson J. Few with STEMI are diagnosed within 10 minutes from first medical contact, and women have longer delay times than men. International Journal of Cardiology Heart & Vasculature. 2020;26:100458.
10. Lawesson SS, Isaksson RM, Ericsson M, Angerud K, Thylen I. Gender disparities in first medical contact and delay in ST-elevation myocardial infarction. BMJ Open. 2018;8:e020225.
11. Prehospital Emergency Care. Implementation of a Novel Prehospital Clinical Decision Tool and ECG Transmission for STEMI. 2024. (Study of 3,153 STEMI activations.)
12. Rao S, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025.
13. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004;109:1223–1225.
14. Scholz KH, et al. Impact of treatment delay on mortality in STEMI patients (FITT-STEMI trial). European Heart Journal. 2018;39(13):1065–1074.
15. Manzo-Silberman S, et al. Longer pre-hospital delays and higher mortality in women with STEMI: the e-MUST Registry. EuroIntervention. 2020.
16. Fabreau GE, et al. Sex Disparities in Diagnostic Evaluation and Revascularization in Patients With Acute Myocardial Infarction — A 15-Year Nationwide Study. Journal of the American Heart Association. 2022;11:e027716.
17. Stehli J, et al. Impact of STEMI Diagnosis and Catheterization Laboratory Activation Systems on Sex- and Age-Based Differences in Treatment Delay. CJC Open. 2021;3:723–732.
18. Lu H, et al. Sex-based disparities in acute myocardial infarction treatment and outcomes. National Institute on Aging / University of Texas / Harvard Medical School. (Study of 1.5M+ patients across 6 countries.)
19. CDC. Heart Disease Facts. Updated October 2024.
20. Gregory P, Kilner T, Lodge S, Paget S. Accuracy of ECG chest electrode placements by paramedics. British Paramedic Journal. 2021;6(1):8–14.
21. Naidu SS, et al. SCAI expert consensus update on best practices in the cardiac catheterization laboratory (endorsed by ACC, AHA, and HRS). 2021.

About C-Booth Innovations

C-Booth Innovations is pioneering precision in cardiac monitoring with the EXG™ Wearable ECG Platform — founded by two emergency room physicians, inspired by the clinical need to improve the standard of patient care. The EXG system is FDA registered, ISO certified, and designed around AHA-compliant standards.

To learn more or schedule a demonstration, visit cboothinnovations.com or call (760) 800-2109.

© 2026 C-Booth Innovations. All rights reserved. | 5835 Avenida Encinas, Suite 118, Carlsbad, CA 92008